Advertisement
The latest 5.19 million dose purchase order is in addition to an initialorder for 3.3 million doses and second order for 3 million doses received bySinovac from the Ministry of Industry and Information Technology of China onSeptember 4, 2009 and September 30, 2009, respectively, for a total of 11.49million doses.
Advertisement
Separately, Sinovac also announced today that it competed and successfullywon the bidding process to supply its seasonal flu vaccine, Anflu, to theShanghai government. This marks Sinovac's entry into a new public market forits seasonal flu vaccine. The purchase plan from the Shanghai governmentreflects an expansion of government purchase programs for the seasonal fluvaccine. As part of the beneficial policies for citizens of Shanghai, certainShanghai citizens will receive inoculation against influenza for free or withcertain allowances.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "Weare very proud to be supplying our H1N1 vaccine to the Chinese government andare confident that we can complete the national H1N1 vaccine stockpiling taskin a timely manner. We continue to work towards our goal of providing citizensof China with affordable, international-quality vaccines. The agreement withthe Shanghai Municipal Center for Disease Control and Prevention brings uscloser to our goal as it opened up another important public market in China."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company thatfocuses on the research, development, manufacture and commercialization ofvaccines that protect against human infectious diseases. Sinovac's vaccineproducts include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A andB), and Anflu(R) (influenza). Panflu(R) and PANFLU.1, Sinovac's pandemicinfluenza vaccine (H5N1) and H1N1 vaccine, have already been approved forgovernment stockpiling. Sinovac is developing vaccines for enterovirus 71,universal pandemic influenza, Japanese encephalitis, and human rabies. Itswholly owned subsidiary, Tangshan Yian, is conducting field trials forindependently developed inactivated animal rabies vaccines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statementsare made under the "safe harbor" provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can beidentified by words or phrases such as "will," "expects," "anticipates,""future," "intends," "plans," "believes," "estimates" and similar statements.Among other things, the business outlook and quotations from management inthis press release contain forward-looking statements. Statements that are nothistorical facts, including statements about Sinovac's beliefs andexpectations, are forward-looking statements. Forward-looking statementsinvolve inherent risks and uncertainties. A number of important factors couldcause actual results to differ materially from those contained in anyforward- looking statement. Sinovac does not undertake any obligation toupdate any forward-looking statement, except as required under applicable law.For more information, please contact: Sinovac Biotech Ltd.: Helen G. Yang Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: [email protected] Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: [email protected] [email protected] Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email: [email protected]
SOURCE Sinovac Biotech Ltd.
